Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163554 | 0.87 | MEN1 (0.44) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL18527956 | 0.85 | MEN1 (0.51) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL186800 | 0.84 | MEN1 (0.53) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL8773482 | 0.84 | MEN1 (0.69) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL1935310 | 0.84 | MEN1 (0.47) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL23931825 | 0.83 | MEN1 (0.50) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL335254 | 0.83 | MEN1 (0.50) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL23116262 | 0.83 | MEN1 (0.51) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL1684422 | 0.83 | MEN1 (0.55) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL15328453 | 0.83 | MEN1 (0.50) | MEN1KMT2AHTTL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106458952-B | Heterocycle sulfamide derivatives and drug containing the heterocycle sulfamide derivatives | EA制药株式会社 | 2019-09-27 | — | — | CN | disclosed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| CN-106458952-A | Heterocyclic sulfonamide derivative and medicine comprising same | EA制药株式会社 | 2017-02-22 | — | — | CN | disclosed |
| US-20160137594-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-05-19 | — | — | US | disclosed |
| US-9273003-B2 | Methods of treating lymphoma and rheumatoid arthritis with cyclopentyl (2S)-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8507543-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-20130030031-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-8304446-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-11-06 | — | — | US | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2295410-A1 | HDAC inhibitor | Chroma Therapeutics Limited (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| EP-1408962-B1 | SUBSTITUTED ISOINDOLES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-03-15 | — | — | EP | disclosed |
| EP-1408962-A1 | SUBSTITUTED ISOINDOLES AND THE USE THEREOF | Bayer HealthCare AG (DE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003007942-A1 | SUBSTITUTED ISOINDOLES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137594-A1 | HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | MEN1 3441/4885KMT2A 32/4885HTT 2000/4885 |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | CCR4, CCR3, CCR1 | MEN1 4632/4885KMT2A 4136/4885HTT 4548/4885 |
| US-20130030031-A1 | Novel Compounds | CYP3A4, CYP3A43, ABCG2 | MEN1 2172/4885KMT2A 4470/4885HTT 1008/4885 |
| US-20100216860-A1 | NOVEL COMPOUNDS | CYP3A4, CYP3A43, ABCG2 | MEN1 2172/4885KMT2A 4470/4885HTT 1008/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | MEN1 349/4885KMT2A 2057/4885HTT 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.